CooperVision Launches MyDay®MiSight® 1-Day Contact Lenses to Slow Myopia Progression in Children
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 06 2026
0mins
Source: Newsfilter
- Product Innovation: CooperVision is set to launch MyDay®MiSight® 1-day contact lenses in the UK and select European markets, combining ActivControl® technology with advanced silicone hydrogel material to slow myopia progression in children, which is expected to significantly enhance the company's market share in pediatric vision management.
- Market Demand: Research indicates that one in two children born today could develop myopia by age 20, highlighting the critical need for early intervention, and the launch of MyDay®MiSight® directly addresses this urgent demand, likely driving sales growth.
- Clinical Support: The ActivControl® technology has demonstrated approximately a 50% reduction in myopia progression in clinical trials, and with hundreds of thousands of children already using this technology, it enhances market trust and acceptance of the new product, further solidifying CooperVision's industry leadership.
- Transition Design: The new lens design not only provides clear vision but also facilitates a smooth transition for children to adult lens wear, leveraging shared materials and specifications with MyDay® lenses, which is expected to boost customer loyalty and long-term sales potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COO
Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is 90.33 USD with a low forecast of 73.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 80.370
Low
73.00
Averages
90.33
High
100.00
Current: 80.370
Low
73.00
Averages
90.33
High
100.00
About COO
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Teva Pharmaceuticals' Request to Delay Paragard Lawsuit Trial Denied by Judge
- Trial Progress: A Georgia federal judge denied Teva Pharmaceuticals' request to delay the Paragard IUD lawsuit trial, ruling that it will proceed on January 20, 2024, marking the first trial in approximately 3,800 lawsuits, which could significantly impact the company's future legal liabilities and financial outlook.
- Litigation Context: Plaintiffs allege that the Paragard device can fracture during removal, leading to injuries and fertility complications, while Teva argues that FDA approval should preempt state law claims, indicating the company's urgency in its legal strategy to appeal for dismissal of the claims.
- Compliance Issues: The judge expressed concern over Teva's five-year delay in updating Paragard's warning labels as mandated by the FDA in 2010, suggesting potential intentionality that could undermine the court's trust in Teva and affect the case's outcome, thereby increasing the company's legal risks.
- Market Reaction: Teva's stock fell 0.21% to $32.72 in the latest trading session, reflecting market concerns about the upcoming trial and its potential financial implications, which may lead to decreased investor confidence.
Continue Reading
Boyar Research Unveils 2026's 'Forgotten Forty' Stocks with High Upside Potential
- Undervalued Stocks: Boyar Research's 'Forgotten Forty' list includes stocks like Uber and Airbnb, which are expected to outperform the market in the coming year, reflecting renewed investor interest in value stocks.
- Tax Law Impact: Atlanta Braves Holdings faces a tax law change effective in 2027 that limits deductions for top executives, potentially reducing profitability and prompting owner John Malone to consider selling the team to mitigate tax implications.
- Market Potential: Markel Group, dubbed the 'baby Berkshire', is under activist pressure to unlock value through share buybacks and operational improvements, with a current share price around $2,000 and an estimated worth of $3,100, indicating strong growth potential.
- Business Split Expectations: Cooper Companies, with a 25% market share in contact lenses, is facing calls for a split to optimize capital allocation, which analysts believe will enhance overall business performance and drive stock price increases.
Continue Reading